New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
08:30 EDTATRCAtriCure posted outstanding Q2 results, says Canaccord
Canaccord said Atricure posted outstanding Q2 results, citing its growth trajectory, its integration of the Estech acquisition, and its investments in education and product development. The firm feels Atricure is undervalued and reiterates its Buy rating and $26 price target on the shares.
News For ATRC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
08:32 EDTATRCAtriCure announces enrollment of first two patients in DEEP study
Subscribe for More Information
07:54 EDTATRCAtriCure underappreciated and undervalued, says Canaccord
Subscribe for More Information
February 23, 2015
16:07 EDTATRCAtriCure sees FY15 revenue $122.5M-$124.5M, consensus $122.43M
Sees FY15 adjusted EBITDA to be a loss in the range of ($7M)-($9M).
16:06 EDTATRCAtriCure reports Q4 EPS (20c), consensus (20c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use